- PR Newswire•22 days ago
ENGLEWOOD, Colo., Aug. 3, 2016 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announced today that it has filed a meeting request and Briefing Document with the FDA to seek guidance on the filing of the company's Biological License Application (BLA) for Ampion™ to treat patients suffering from pain caused by severe Osteoarthritis (OA) of the knee. In the second quarter of this year, Ampio submitted their Chemistry Manufacturing and Controls (CMC) documents for Ampion™ with the FDA, and requested the Agency provide any related guidance. Ampio also announced that the STRUT Study that treated pain due to OA of the knee with multiple injections of Ampion™, authored by Dr. John Schwappach, the trials Principal Investigator, was accepted for publication in the peer-reviewed journal "Orthopedics." As soon as the journal is in print, we will post the article on Ampio's website.
- Associated Press•22 days ago
The Englewood, Colorado-based company said it had a loss of 10 cents per share. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. ...
- TheStreet.com•last month
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Ampio Pharmaceuticals, Inc. (AMPE)
NYSE MKT - NYSE MKT Real Time Price. Currency in USD
|Bid||0.93 x 1000|
|Ask||0.94 x 300|
|Day's Range||0.90 - 0.99|
|52wk Range||0.84 - 4.32|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-1.54|
|Avg Vol (3m)||886,315|
|Dividend & Yield||N/A (N/A)|